Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRN101099 in HER2-Positive Solid Tumors
NCT06806982Phase 1Recruiting
- Sponsor
- Voronoi
- Start
- Feb 2025
- Primary completion
- May 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VRN101099 in HER2-positive solid tumor, sponsored by Voronoi. Primary endpoints: Maximum Tolerated Dose up to 2 years, Adverse Events and Serious Adverse Events up to 2 years and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
VRN101099
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT06806982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806982.